Goodwill is not amortized but is subject to an annual impairment test. Goodwill has been assigned to reporting units within the reportable segments. The Company assesses the carrying value of goodwill annually, or more often if events or changes in circumstances indicate there may be impairment.

Impairment testing is performed at a reporting unit level. During the six months ended March 31, 2022, goodwill decrease

d $629, reflecting: (i) a $376 decrease in Diagnostics segment

goodwill

; and (ii) a $253 decrease in Life Science segment

goodwill, primarily due to foreign currency translation

. During the six months ended March 31, 2022, the Company did not observe any triggering events or substantive changes in circumstances requiring the need for an interim impairment assessment.

A summary of other intangible assets, net, subject to amortization is as follows:


	March 31, 2022				September 30, 2021
	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Manufacturing technologies, core products and cell lines	$	62,385	$	24,510	$	62,416	$	22,633
Trade names, licenses and patents		18,451		10,070		18,489		9,492
Customer lists, customer relationships and supply agreements		54,755		22,021		54,941		19,649
Non-compete agreements		110		42		110		31

Total	$	135,701	$	56,643	$	135,956	$	51,805

The aggregate amortization expense for these other intangible assets was $2,483 and $2,142 for the three months ended March 31, 2022 and 2021, respectively, and $4,966 and $4,363 for the six months ended March 31, 2022 and 2021, respectively. The estimated aggregate amortization expense for these other intangible assets for each of the fiscal years through fiscal 2027 is as follows: remainder of fiscal 2022 – $4,960, fiscal 2023 – $9,905, fiscal 2024 – $9,900, fiscal 2025 – $9,895, fiscal 2026 – $8,900, and fiscal 2027 – $6,645.